Načítá se...
Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with impro...
Uloženo v:
| Vydáno v: | Cancer Manag Res |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513839/ https://ncbi.nlm.nih.gov/pubmed/28744160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S139305 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|